Depemokimab Shows Sustained Asthma Remission Benefit
New data reveals a significant portion of patients maintain clinical remission over two years of treatment.
Updated on Oct. 21, 2026 in Asthma
Live Poll
Does achieving early clinical remission with asthma medication increase your trust in the therapy's long-term effectiveness?
Recent clinical data demonstrates that patients with severe asthma can maintain multi-component clinical remission for two years using depemokimab. Analysis indicates that those achieving initial success show sustained improvements in lung function and reduced exacerbations.
Why it matters
Achieving clinical remission represents a critical shift in asthma management from symptom control to long-term stabilization. These results highlight the potential for extended treatment efficacy in patients who successfully reach remission in their first year.
Patients achieving year 1 remission recorded an annualized exacerbation rate of 0.19 compared to 0.69 for others, alongside a 379 mL improvement in FEV1. Remission is defined by four metrics including no corticosteroid use and an ACQ-5 score below 1.5.
The details
The analysis combined findings from the 52-week SWIFT-1 and SWIFT-2 trials with the 52-week AGILE open-label extension study. Patients successfully maintaining remission experienced notable improvements in quality of life metrics, including an SGRQ score improvement of -23.57 points.
Timeline
December 2025: Depemokimab received FDA approval for severe asthma.
October 20, 2026: Integrated analysis was presented at the CHEST 2026 Annual Meeting.
Health Landscape
This analysis extends the findings of the AGILE open-label extension study by integrating earlier clinical trial phases to confirm two-year remission outcomes. It marks a significant milestone in documenting how biological therapies can move severe asthma management toward sustained clinical remission.
Patients prescribed depemokimab for severe asthma may see improvements in lung function and a decrease in daily symptom scores if they achieve early remission. These results suggest that long-term adherence could significantly lower the frequency of asthma exacerbations and reliance on oral corticosteroids.
The takeaway
Maintaining remission for two years can lead to substantial improvements in respiratory health and daily quality of life for severe asthma patients. Patients should consult with their healthcare providers regarding the latest clinical evidence to understand if long-term biological therapy is appropriate.
Further reading
For more information on the management of chronic respiratory conditions, visit our Asthma section.
Source note: This article includes information reported by Hcplive.
Live Poll
Does achieving early clinical remission with asthma medication increase your trust in the therapy's long-term effectiveness?
